Quarterly report [Sections 13 or 15(d)]

STOCKHOLDERS??? EQUITY

v3.26.1
STOCKHOLDERS’ EQUITY
 9 Months Ended
Mar. 31, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 14 - STOCKHOLDERS’ EQUITY

 

During the three and nine months ended March 31, 2026, the Company issued 10,620 and 30,084 shares of common stock, respectively, to the independent Board of Directors as part of their board compensation. The grant date fair value was $36,000 and $108,000, respectively, and was recorded as compensation expense in the accompanying consolidated financial statements.

 

During the three and nine months ended March 31, 2026, the Company issued 14,943 shares of common stock to one officer of the Company for his accrued bonus for the fiscal year ended June 30, 2024 pursuant to the bonus policy of the Company. The grant date fair value of the shares was $37,955, and was recorded as compensation expense in the consolidated financial statements for the fiscal year ended June 30, 2024.

 

During the three and nine months ended March 31, 2026, the Company issued 7,168 and 20,448 shares of common stock to a consultant pursuant to the terms of its consultancy agreement. The grant date fair value of the shares was $25,000 and $75,000, respectively, and was recorded as compensation expense in the accompanying consolidated financial statements.

 

During the nine months ended March 31, 2026, the Company issued 20,000 shares of common stock to employees pursuant to the terms of their employment agreements. The grant date fair value was $84,400 and was recorded as compensation expense in the accompanying consolidated financial statements.

 

 

NETSOL TECHNOLOGIES, INC.

Notes to Condensed Consolidated Financial Statements

March 31, 2026

(Unaudited)

 

Stock Grants

 

The following table summarizes stock grants awarded as compensation:

 

   

# Number of

shares

    

Weighted

Average Grant

Date Fair Value

($)

  
Unvested, June 30, 2025     -     $ -  
Granted     65,027     $ 3.54  
Vested     (65,027 )   $ 3.54  
Unvested, March 31, 2026     -     $ -  

 

For the three and nine months ended March 31, 2026, the Company recorded compensation expense of $61,000 and $267,400, respectively. For the three and nine months ended March 31, 2025, the Company recorded compensation expense of $39,750 and $79,500, respectively. The weighted average grant date fair value is determined by the Company’s closing stock price on the grant date.